S2Medical AB (publ) has received the information from the European Patent Office (EPO) that it intends to approve the patenting of the company's AMP technology in Europe. This patent protection can, through a so-called unitary patent, provide patent protection in up to 25 European countries. The patent application in question includes an antimicrobial peptide that has shown to significantly improve the efficiency of existing antibiotics and provide the opportunity for dismissed antibiotics to again be used, even when treating multi-resistant bacteria.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0385 SEK | +4.05% |
|
+6.94% | -35.83% |
05-17 | S2Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-20 | S2Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
-35.83% | 1.01M | |
-5.81% | 180B | |
-1.63% | 106B | |
-4.14% | 67.55B | |
-6.56% | 46.11B | |
+13.22% | 45.79B | |
+6.13% | 41.61B | |
+19.93% | 31.07B | |
+13.61% | 24.77B | |
-5.36% | 24.27B |
- Stock Market
- Equities
- S2M Stock
- News S2Medical AB
- EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology